Chiasma Files Mycapssa European Application For Acromegaly

by Vandana Singh, Benzinga Editor

June 29, 2021 7:03 AM | 1 min read | Make a Comment

Chiasma Inc CHMA submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly.
The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).
Recently, the company announced positive patient-reported outcomes data from its MPOWERED trial, demonstrating that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs to Mycapssa.
Price Action: CHMA shares are down 0.2% at $4.7 during the premarket session on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Acromegaly Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.